Table 1.
Rates of progression of brain atrophy in frontal and temporal lobes before (2010–2015) and while receiving treatment with LMTM (2015–2019) compared with rates of atrophy calculated from data reported by Chen et al. data [8]
| Subjects | Frontal | Temporal | ||
| Case | Lobe (cm3/y, [rate % /y]) | Change in rate (%) | Lobe (cm3/year, [rate % /y]) | Change in rate (%) |
| 2010–2015 | –1.54 [–0.88%] | –0.72 [–0.73%] | ||
| 2015–2019 | –0.52 [–0.30%] | –66.3 | –0.28 [–0.28%] | –61.0 |
| Case | Cortex GM (cm3/y, [rate %/y]) | Change in rate (%) | Cortex GM (cm3/y, [rate %/y]) | Change in rate (%) |
| 2010–2015 | –0.85 [–0.86%] | –0.54 [–0.91%] | ||
| 2015–2019 | –0.29 [–0.29%] | –65.9 | –0.21 [–0.35%] | –61.1 |
| Chen et al. | Cortex GM (cm3/y, [rate %/y]) | Change in rate (%) | Cortex GM (cm3/year, [rate %/y]) | Change in rate (%) |
| Asymptomatic | –0.81 [–0.57%] | –0.94 [–0.74%] | ||
| Converter | –1.44 [–0.84%] | +77.8 | –1.62 [–1.42%] | +72.3 |
| Non-Carrier | –0.55 [–0.40%] | –0.41 [–0.35%] | ||